Cramer’s scientific breakthroughs include the invention of Comparative Molecular Field Analysis (CoMFA®), the first and most widely-used 3D-QSAR technique for molecular discovery. Researchers use CoMFA to build statistical and graphical models that relate the chemical and biological properties of molecules to their 3D structures and the 3D steric and electrostatic properties. These models are then used to predict the activity of novel compounds. This information helps researchers to decide which molecules will likely make the best new drug candidates. This development earned Cramer one of the earliest cheminformatics patents. He continues to refine this technique through his work on topomeric descriptors and other QSAR innovations.
“Dick Cramer’s accomplishments have had, and continue to have, a substantial impact across the drug discovery field. One small indication is that today ‘CoMFA’ is a household word within our community,” said Dr.
“I am grateful to my peers for recognizing my work and bestowing this honor on me. It is really gratifying to have created a product like CoMFA that is still being used to predict small molecule bioactivity 25 years later. I am fortunate to be able to do work that I love, in a challenging field, with such supportive colleagues,” said Cramer.
Cramer began his career as a bench chemist at
After completing his fellowship, Cramer performed QSAR design studies for SmithKline for more than 10 years, serving in increasingly senior roles, which culminated in his appointment as the company’s first research fellow. Cramer founded and led SmithKline’s computer-aided drug design group, championing the introduction of molecular graphics.
In 1983, Cramer joined
During his distinguished career, Cramer has published 55 scientific papers and given numerous presentations both in the U.S. and around the world.
Cramer received his bachelor of arts in chemistry and physics from
Certara is dedicated to improving human health by delivering a broad spectrum of software products and consulting services, spanning molecular discovery to clinical development, with special focus on supporting translational approaches to drug development. A leading provider of model-based drug development tools, Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit www.certara.com.
Diana O’Rourke, 314-951-3310
Director of Marketing
Rana Healthcare Solutions